Vedanta strikes deal with Janssen for IBD therapy
This article was originally published in Scrip
Janssen, a subsidiary of Johnson & Johnson, has entered a license agreement with Vedanta Biosciences to develop the latter firm's lead microbiome pharmaceutical candidate, VE202, for inflammatory bowel disease (IBD).
You may also be interested in...
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.
Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.